Sunovion Seizure Drug Accepted for FDA Review

The pharmaceutical firm has resubmitted STEDESA, a once-daily adjunctive therapy for partial-onset seizures, for review by the agency.

Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has accepted for review the Company’s New Drug Application resubmission for STEDESA (eslicarbazepine acetate) for use as a once-daily adjunctive therapy in the treatment of partial-onset seizures in patients 18 years and older with epilepsy. STEDESA is the proposed trade name for eslicarbazepine acetate.

No votes yet

Seizure Treatment Fycompa Attains FDA Approval

The tablets, from Eisai Inc., are designed to treat partial onset seizures in patients with epilepsy ages 12 years and older.

Partial seizures are the most common type of seizure seen in people with epilepsy. Epilepsy is a brain disorder in which there is abnormal or excessive activity of nerve cells in the brain. Partial seizures affect only a limited or localized area of the brain, but can spread to other parts of the brain. Seizures cause a wide range of symptoms, including repetitive limb movements (spasms), unusual behavior, and generalized convulsions with loss of consciousness.

No votes yet
Syndicate content